 | Mizuki Nishino |
Prominent publications by Mizuki Nishino
Importance: Programmed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potentially life-threatening adverse event. Little is known about its incidence across different tumor types and treatment regimens.
Objective: To compare the incidence of PD-1 inhibitor-related pneumonitis among different tumor types and therapeutic regimens.
Data Sources: A PubMed search through November 10, 2015, and a review of references from relevant articles. For the ...
| Also Ranks for: Incidence Pneumonitis | cell death | combination therapy | advanced cancer | nsclc rcc |
OBJECTIVE: The purpose of this article is to compare the recently published revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) to the original guidelines (RECIST 1.0) for advanced non-small cell lung cancer (NSCLC) after erlotinib therapy and to evaluate the impact of the new CT tumor measurement guideline on response assessment.
MATERIALS AND METHODS: Forty-three chemotherapy-naive patients with advanced NSCLC treated with erlotinib in a single-arm ...
| Also Ranks for: Solid Tumors | tumor response | recist recist 11 | cell lung | target lesions |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
[ PUBLICATION ]
OBJECTIVE: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 has been rapidly accepted in clinical trials as a standard measure to assess tumor response to therapy and is expected to improve response assessment, especially in genomically defined patients. The impact of RECIST 1.1 was compared with RECIST 1.0 in non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors.
MATERIALS AND ...
| Also Ranks for: Recist Recist 11 | nsclc patients | egfr mutations | target lesions | kinase inhibitors |
BACKGROUND: Cigarette smoking is associated with emphysema and radiographic interstitial lung abnormalities. The degree to which interstitial lung abnormalities are associated with reduced total lung capacity and the extent of emphysema is not known.
METHODS: We looked for interstitial lung abnormalities in 2416 (96%) of 2508 high-resolution computed tomographic (HRCT) scans of the lung obtained from a cohort of smokers. We used linear and logistic regression to evaluate the associations ...
| Also Ranks for: Interstitial Lung Abnormalities | lung volumes | 95 p0001 | emphysema smokers | hrct scans |
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
[ PUBLICATION ]
PURPOSE: BRAF mutations are found in a subset of non-small cell lung cancers (NSCLC). We examined the clinical characteristics and treatment outcomes of patients with NSCLC harboring BRAF mutations.
EXPERIMENTAL DESIGN: Using DNA sequencing, we successfully screened 883 patients with NSCLC for BRAF mutations between July 1, 2009 and July 16, 2012. Baseline characteristics and treatment outcomes were compared between patients with and without BRAF mutations. Wild-type controls consisted ...
| Also Ranks for: Braf Mutations | patients nsclc | small cell | egfr kras | dna sequencing |
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma ...
| Also Ranks for: Solid Tumors | cancer immunotherapy | response evaluation criteria | clinical benefit | recist v11 |
PURPOSE: Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in clinical trials of EGFR-TKI published in 2003-2017, and performed subgroups analyses to identity predisposing factors.
METHODS: Ovid-MEDLINE and EMBASE search up to 4/17/17 using the keywords, "erlotinib", "gefitinib", "afatinib", "osimertinib", and "lung cancer", resulted in a total of 153 eligible trial ...
| Also Ranks for: Lung Cancer | incidence pneumonitis | 153 cohorts | egfr tki | tyrosine kinase |
OBJECTIVE. Response Evaluation Criteria in Solid Tumors (RECIST) is the most widely accepted method to objectively assess response to therapy in renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. Both RECIST 1.0 and 1.1 have been used to assess response to VEGF-targeted therapies; however, systematic comparisons are lacking. MATERIALS AND METHODS. Sixty-two patients with metastatic RCC treated with VEGF-targeted therapies were ...
| Also Ranks for: Recist Recist 11 | renal cell | solid tumors | target lesions | response assessment |
OBJECTIVES: To quantitatively compare diaphragmatic motion during tidal breathing in a standing position between chronic obstructive pulmonary disease (COPD) patients and normal subjects using dynamic chest radiography.
MATERIALS AND METHODS: Thirty-nine COPD patients (35 males; age, 71.3±8.4years) and 47 normal subjects (non-smoker healthy volunteers) (20 males; age, 54.8±9.8years) underwent sequential chest radiographs during tidal breathing using dynamic chest radiography with a flat ...
| Also Ranks for: Normal Subjects | copd patients | dynamic chest radiography | diaphragmatic motion | tidal breathing |
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
[ PUBLICATION ]
INTRODUCTION: Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.
METHODS: NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20 ...
| Also Ranks for: Exon 20 Insertions | lung cancers | harboring egfr | clinical characteristics | nsclc patients |
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
[ PUBLICATION ]
PURPOSE: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact on sequential MET TKI therapy outcomes in patients with metastatic MET exon 14-mutant NSCLC.
EXPERIMENTAL DESIGN: Genomic alterations occurring at the time of progression on MET TKIs were studied using plasma and tissue next-generation sequencing (NGS).
RESULTS: A ...
| Also Ranks for: Acquired Resistance | tyrosine kinase inhibitors | molecular mechanisms | exon 14 | –mutant nsclc |
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression
[ PUBLICATION ]
BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy. Whether higher PD-L1 levels within the expression range of 50%-100% predict for even greater benefit to pembrolizumab is currently unknown.
PATIENTS AND METHODS: In this multicenter retrospective analysis, we analyzed the impact of PD-L1 expression ...
| Also Ranks for: L1 Expression | cell lung | tumor carcinoma | pembrolizumab patients | humanized antineoplastic agents |
BACKGROUND: The study investigated whether tumor volume changes at 8 weeks of therapy is associated with outcomes in advanced non-small-cell lung cancer (NSCLC) patients harboring sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs).
METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up ...
| Also Ranks for: 8 Weeks | tumor volume | cell lung | egfr tki | longer survival |
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
[ PUBLICATION ]
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated ...
| Also Ranks for: Mutant Lung | inhibitor resistance | stk11 lkb1 | neoplasm humans | pd1 pdl1 |
IMPORTANCE: Interstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total lung capacity. However, to our knowledge, an association with mortality has not been previously investigated.
OBJECTIVE: To investigate whether interstitial lung abnormalities are associated with increased mortality.
DESIGN, SETTING, AND POPULATION: Prospective cohort studies of 2633 participants from the FHS (Framingham Heart Study; ...
| Also Ranks for: Interstitial Lung Abnormalities | allcause mortality | pulmonary disease | higher rate | ages reykjavik |
Mizuki Nishino: Influence Statistics
| Concept | World rank |
|---|---|
| 44 validity | #1 |
| 5fu values | #1 |
| clinical oncology recist11 | #1 |
| major standardized criteria | #1 |
| –mutant nsclc crizotinib | #1 |
| genomic medicine histiocytosis | #1 |
| highgrade pneumonitis | #1 |
| nonsquamous nsclcs | #1 |
| cancers trc | #1 |
| pancreatic adrenal atrophy | #1 |
| qualifying smoking | #1 |
| enteritis colitis | #1 |
| recist11 step | #1 |
| pneumonitis higher | #1 |
| patients colitis enteritis | #1 |
| recist 11 recist | #1 |
| vsegmented | #1 |
| pneumonitis hepatitis | #1 |
| estimated tumour volumetry | #1 |
| conditions clinical scenarios | #1 |
| pseudoprogression incidence | #1 |
| recist chapter | #1 |
| therapy response imaging | #1 |
| hormones oncology | #1 |
| role multidisciplinary approach | #1 |
| 117–583 months | #1 |
| gepnets role | #1 |
| vegf molecular | #1 |
| inhibitors familiarity | #1 |
| enteritis hepatitis | #1 |
| comparison recist11 | #1 |
| specific limitations setting | #1 |
| appearance tumor progression | #1 |
| response assessment recist | #1 |
| nishino recist | #1 |
| vsegmented scalene ellipsoid | #1 |
| patients precision therapy | #1 |
| longer mpfs | #1 |
| tegafur tomography antimetabolites | #1 |
| percent measurements | #1 |
| –mutant nsclc | #1 |
| recist mass | #1 |
| individualized trc | #1 |
| colitis enteritis hepatitis | #1 |
| molecular targeting agents | #1 |
| immunotherapy nishino | #1 |
| antiangiogenic mtts | #1 |
| lymphoma hematologic malignancies | #1 |
| immunooncology journal | #1 |
| case lanehamilton syndrome | #1 |
Key People For Interstitial Lung Abnormalities
Mizuki Nishino:Expert Impact
Concepts for whichMizuki Nishinohas direct influence:Interstitial lung abnormalities, Lung cancer, Lung abnormalities, Cell lung, Interstitial lung, Solid tumors, Tumor volume, Coronal reformations.
Mizuki Nishino:KOL impact
Concepts related to the work of other authors for whichfor which Mizuki Nishino has influence:Lung cancer, Immune checkpoint inhibitors, Small cell, Pulmonary fibrosis, Computed tomography, Solid tumors, Rheumatoid arthritis.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |